References
- Alaiya AA, Oppermann M, Langridge J, et al (2001). Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry. Cell Mol Life Sci, 58, 307-11. https://doi.org/10.1007/PL00000858
- Balaburski GM, Leu JI, Beeharry N, et al (2013). A modifed HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res, 11, 219-29. https://doi.org/10.1158/1541-7786.MCR-12-0547-T
- Bitting RL, Armstrong AJ (2013). Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer, 20, R83-99. https://doi.org/10.1530/ERC-12-0394
- Daugaard M, Rohde M, Jaattela M (2007). The heat shock protein 70 family: Highly homologous proteins with overlapping and distinct functions. FEBS Lett, 581, 3702-10. https://doi.org/10.1016/j.febslet.2007.05.039
- Davenport EL, Zeisig A, Aronson LI, et al (2010). Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia, 24, 1804-7. https://doi.org/10.1038/leu.2010.168
- DeSantis C, Naishadham D, Jemal A (2013). Cancer statistics for African Americans, 2013. CA Cancer J Clin, 63, 151-66. https://doi.org/10.3322/caac.21173
- Di Lorenzo G, Autorino R, Figg WD, et al (2007). Hormone-refractory prostate cancer: Where are we going? Drugs, 67, 1109-24. https://doi.org/10.2165/00003495-200767080-00002
- Evans CG, Chang L, Gestwicki JE (2010). Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem, 53, 4585-602. https://doi.org/10.1021/jm100054f
- Garcia JA, Rini BI (2012). Castration-resistant prostate cancer: Many treatments, many options, many challenges ahead. Cancer, 118, 2583-93. https://doi.org/10.1002/cncr.26582
- Garrido C, Schmitt E, Cande C, et al (2003). HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle, 2, 579-84.
- Goloudina AR, Demidov ON, Garrido C (2012). Inhibition of HSP70: a challenging anti-cancer strategy. Cancer Lett, 325, 117-24. https://doi.org/10.1016/j.canlet.2012.06.003
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Lebret T, Watson RW, Fitzpatrick JM (2003). Heat shock proteins: their role in urological tumors. J Urol, 169, 338-46.
- Li HL, Zheng XZ, Wang HP, et al (2009). Ultrasound-targeted microbubble destruction enhances AAV-mediated gene transfection in human RPE cells in vitro and rat retina in vivo. Gene Ther, 16, 1146-53. https://doi.org/10.1038/gt.2009.84
- Matthias MP (2013). Hsp70 chaperone dynamics and molecular mechanism. Trends Biochemical Sciences, 38, 507-14. https://doi.org/10.1016/j.tibs.2013.08.001
- McConnell JR, McAlpine SR (2013). Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorg Med Chem Lett, 23, 1923-28. https://doi.org/10.1016/j.bmcl.2013.02.014
- McNamara JO 2nd, Andrechek ER, Wang Y, et al (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol, 24, 1005-15. https://doi.org/10.1038/nbt1223
- Meng L, Hunt C, Yaglom JA, et al (2011). Heat shock protein Hsp72 plays role in Her2-induced mammary tumorigenesis. Oncogene, 30, 2836-45. https://doi.org/10.1038/onc.2011.5
- Pai SI, Lin YY, Macaes B, et al (2006). Prospects of RNA interference therapy for cancer. Gene Ther, 13, 464-77. https://doi.org/10.1038/sj.gt.3302694
- Powers MV, Clarke PA, Workman P (2008). Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell, 14, 250-62. https://doi.org/10.1016/j.ccr.2008.08.002
- Powers MV, Jones K, Barillari C, et al (2010). Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle, 9, 1542-50. https://doi.org/10.4161/cc.9.8.11204
- Rerole AL, Gobbo J, De Thonel A, et al (2011). Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res, 71, 484-95. https://doi.org/10.1158/0008-5472.CAN-10-1443
- Rerole AL, Jego G, Garrido C (2011). Hsp70: anti-apoptotic and tumorigenic protein. Methods Mol Biol, 787, 205-30. https://doi.org/10.1007/978-1-61779-295-3_16
- Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
- Stangl S, Gehrmann M, Riegger J, et al (2011). Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci USA, 108, 733-38. https://doi.org/10.1073/pnas.1016065108
- Suzuki R, Oda Y, Utoguchi N, et al (2011). Progress in the development of ultrasound-mediated gene delivery systems utilizing nano- and microbubbles. J Control Release, 149, 36-41. https://doi.org/10.1016/j.jconrel.2010.05.009
- Tachibana K, Uchida T, Ogawa K, et al (1999). Induction of cell-membrane porosity by ultrasound. Lancet, 353, 1409.
- Whitesell L, Lindquist SL (2005). HSP90 and the chaperoning of cancer. Nat Rev Cancer, 5, 761-72. https://doi.org/10.1038/nrc1716
- Xie W, Liu S, Su H, et al (2010). Ultrasound microbubbles enhance recombinant adeno-associated virus vector delivery to retinal ganglion cells in vivo. Acad Radiol, 17, 1242-48. https://doi.org/10.1016/j.acra.2010.05.008
- Yao YD, Sun TM, Huang SY, et al (2012). Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med, 4, 130ra48.
-
Zheng X, Du L, Wang H, et al (2012). A novel approach to attenuate proliferative vitreoretinopathy using ultrasoundtargeted microbubble destruction and recombinant adenoassociated virus-mediated RNA interference targeting transforming growth factor-
${\beta}2$ and platelet-derived growth factor-B. J Gene Med, 14, 339-47. https://doi.org/10.1002/jgm.2629 - Zuiderweg ER, Bertelsen EB, Rousaki A, et al (2013). Allostery in the Hsp70 chaperone proteins. Top Curr Chem, 328, 99-153.
Cited by
- Evaluation of Antimetastatic Effect of lncRNA-ATB siRNA Delivered Using Ultrasound-Targeted Microbubble Destruction vol.35, pp.8, 2016, https://doi.org/10.1089/dna.2016.3254
- shRNA Transfection and TAE in the Treatment of Hepatic Cancer vol.2019, pp.2314-6141, 2019, https://doi.org/10.1155/2019/1937460